Activity from announced rounds
Circle Pharma discovers macrocycle medicines for cancer and other serious diseases using its MXMO platform, which combines computational, structure-based design with synthetic chemistry to create cell-permeable compounds against difficult protein targets. Its lead programs are investigational and at discovery or preclinical stages.
A clinical-stage immunotherapy company is advancing an engineered CTLA-4 antibody for earlier cancer treatment.
Superluminal Medicines combines structural biology, protein dynamics, machine learning and experimental testing to discover small-molecule drugs for difficult G protein-coupled receptor targets. Its pipeline focuses on endocrine and cardiometabolic diseases, including rare genetic and hypothalamic obesity.
Typewriter Therapeutics is developing an all-RNA gene-writing platform that inserts therapeutic genes at a defined genomic site without viral vectors or double-strand DNA breaks. Its programs target in vivo engineered CAR-T cells and gene insertion for severe genetic diseases, including liver disorders.
Develops oligonucleotide therapeutics targeting chronic hepatitis B
Develops immunotherapies that selectively deplete cytotoxic T cells to treat autoimmune diseases
Develops human-derived antibody therapeutics for atopic dermatitis and inflammatory disease
Develops fungal genome-derived therapeutics for organ transplant rejection
Develops treatments for serious respiratory diseases
Develops bispecific antibody therapies for retinal vascular diseases including diabetic macular edema and wet AMD
Develops broad-spectrum antiviral prophylactic therapies for respiratory infections
Develops hormonal and non-hormonal male contraceptives for men and couples globally
Clinical-stage company developing neonatal cardiac progenitor cell therapies for Duchenne-associated cardiomyopathy
Develops inobrodib, a first-in-class oral p300/CBP inhibitor for relapsed or refractory multiple myeloma
Develops highly targeted, small molecule medicines for cancer and rare diseases
Develops first- and best-in-class antibody-drug conjugates (ADCs) for cancer treatment
Provides CAR-T and other advanced treatment delivery in community outpatient settings
Advancing next-generation therapeutics for migraine and other headache disorders
Developing a next-generation pertussis vaccine candidate BPZE1
Develops modular compact fusion machines for clean energy applications
Develops inhaled therapies for severe respiratory diseases
Develops medicines targeting historically undruggable protein targets in cancer